A randomized, double-blind, phase 3 trial of MK-7684A plus chemotherapy versus pembrolizumab plus chemotherapy as first-line therapy for metastatic non–small cell lung cancer (NSCLC): KeyVibe-007.

Authors

Marina Chiara Garassino

University of Chicago Medicine & Biological Sciences, Knapp Center for Biomedical Discovery (KCBD), Chicago, IL

Marina Chiara Garassino , Enriqueta Felip , Mark M. Awad , Wei Wang , Sung Jin Kim , Maria Catherine Pietanza , Delvys Rodriguez-Abreu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

STAR-121: A phase 3, randomized study of domvanalimab (DOM) and zimberelimab (ZIM) in combination with chemotherapy vs pembrolizumab (pembro) and chemotherapy in patients with untreated metastatic non-small cell lung cancer (mNSCLC) with no actionable gene alterations.

First Author: Delvys Rodriguez-Abreu

insert_chart_outlined

Poster

2016 ASCO Annual Meeting

bookmark_border

Avelumab (MSB0010718C; anti-PD-L1) vs platinum-based doublet as first-line treatment for metastatic or recurrent PD-L1-positive non-small-cell lung cancer: The phase 3 JAVELIN Lung 100 trial.

First Author: Martin Reck

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

A randomized, double blinded, multicenter phase 3 study of platinum-based chemotherapy with or without QL1706 as adjuvant therapy in completely resected stage II-IIIb NSCLC.

First Author: Yuming Zhu

insert_chart_outlined

Poster

2020 ASCO Virtual Scientific Program

bookmark_border

A phase II randomized study of telaglenastat, a glutaminase (GLS) inhibitor, versus placebo, in combination with pembrolizumab (Pembro) and chemotherapy as first-line treatment for KEAP1/NRF2-mutated non-squamous metastatic non-small cell lung cancer (mNSCLC).

First Author: Ferdinandos Skoulidis